JPXマーク
ホーム 市場調査レポートについて 医薬品 トランスフォーミング成長因子の世界市場
表紙：トランスフォーミング成長因子の世界市場

トランスフォーミング成長因子の世界市場

Transforming Growth Factors
発行
Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
発行日
ページ情報
英文 481 Pages
納期
即日から翌営業日
商品コード
1792872
  • 適宜更新あり 本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 翻訳ツール提供対象 PDF対応AI翻訳ツールの無料貸し出しサービスのご利用が可能です
全表示
概要
目次
関連レポート

概要

トランスフォーミング成長因子の世界市場は2030年までに5億6,020万米ドルに達する見込み

2024年に4億590万米ドルと推定されるトランスフォーミング成長因子の世界市場は、2024年から2030年にかけてCAGR 5.5%で成長し、2030年には5億6,020万米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるアクチビンは、CAGR6.1%を記録し、分析期間終了時には3億1,350万米ドルに達すると予測されます。骨形質転換タンパク質セグメントの成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は1億1,060万米ドルと推定、中国はCAGR8.8%で成長予測

米国のトランスフォーミング成長因子市場は、2024年に1億1,060万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.8%として、2030年までに1億1,310万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.5%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界のトランスフォーミング成長因子市場- 主要動向と促進要因のまとめ

なぜトランスフォーミング成長因子は再生医療の最前線にいるのか？

トランスフォーミング成長因子（TGFs）、特にTGF-βとTGF-αは、細胞の成長、分化、免疫反応を制御する極めて重要なシグナル伝達タンパク質です。組織修復、線維化、血管新生、炎症において重要な役割を果たすTGFは、再生医療、腫瘍学、免疫学にわたる治療研究の中心となっています。TGFは細胞外マトリックスを調節し、創傷治癒、臓器再生、免疫寛容に関与する経路を活性化する上で重要な役割を果たしています。

医薬品開発においては、TGFはアゴニストとアンタゴニストの両方の用途をターゲットとしています。過剰発現は線維化や腫瘍の進行に関係するが、制御された調節は多発性硬化症、慢性潰瘍、心臓リモデリングなどの疾患において治療の可能性を示しています。TGFの多機能性は、足場の機能化や生物活性インプラントコーティングなど、組織工学における新たなアプローチを解き放ちつつあり、TGFシグナル伝達を活用して組織統合や血管新生を促進します。

治療への応用と送達方法はどのように進化しているのか？

バイオテクノロジー研究は、標的外効果や疾患促進カスケードを回避するために、TGFシグナル伝達を微調整することにますます焦点が当てられています。モノクローナル抗体、リガンドトラップ、低分子阻害剤が、肺線維症や膵臓がんなどの病態におけるTGF-β活性を選択的にブロックするために開発されています。逆に、組換え成長因子やTGF担持ナノ粒子は、整形外科や皮膚科での組織修復を促進するために採用されています。

ハイドロゲルマトリックス、移植可能なバイオマテリアル、遺伝子治療ベクターなどの局所ドラッグデリバリーの進歩は、全身毒性や投与量制御に関する課題の克服に役立っています。これらのデリバリー戦略により、TGFの部位特異的な活性化または阻害が可能となり、治療成績が向上します。幹細胞移植やCAR-T細胞調節のような先進的細胞治療へのTGFsの統合もまた、個別化医療や精密医療のフロンティアとして浮上しています。

トランスフォーミング成長因子市場の成長はいくつかの要因に牽引されている...

成長の原動力となっているのは、再生医療、腫瘍学、免疫療法における用途の拡大と、バイオマテリアルをベースとしたドラッグデリバリーシステムにおける使用の増加です。組換えタンパク質工学と遺伝子調節ツールの進歩により、標的を絞ったTGF操作が可能になりつつあります。慢性創傷治療、組織工学、線維症関連疾患研究への投資が増加し、臨床パイプラインの開発が加速しています。さらに、オルガノイドや3D細胞培養プラットフォームにおける機能的生体分子の需要が、TGFシグナル伝達タンパク質に対する商業的・治療的関心をさらに高めています。

セグメント

製品（アクチビン、骨形質転換タンパク質、TGF-βタンパク質）、グレード（GMPグレード、非GMPグレード）、用途（がん研究用途、血液学研究用途、創傷治癒研究用途、皮膚科学研究用途、心血管疾患・糖尿病用途、細胞治療・生体外製造用途、その他用途）、最終用途（製薬・バイオテクノロジー企業最終用途、研究所・学術機関最終用途、CMO・CDMO最終用途）

調査対象企業の例

  • Abcam plc
  • Abnova Corporation
  • Abzena, Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology
  • Creative Biomart
  • GenScript Biotech Corporation
  • GenScript ProBio
  • Merck KGaA
  • Novoprotein Scientific
  • PeproTech, Inc.
  • Peptide Institute, Inc.
  • ProSpec-Tany TechnoGene Ltd
  • Proteintech Group Inc.
  • R&D Systems（Bio-Techne）
  • RayBiotech, Inc.
  • Sigma-Aldrich（Merck）
  • Sino Biological Inc.
  • Stemcell Technologies Inc.
  • Thermo Fisher Scientific

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次

Product Code: MCP38242

Global Transforming Growth Factors Market to Reach US$560.2 Million by 2030

The global market for Transforming Growth Factors estimated at US$405.9 Million in the year 2024, is expected to reach US$560.2 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Activin, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$313.5 Million by the end of the analysis period. Growth in the Bone Transforming Morphogenetic Proteins segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$110.6 Million While China is Forecast to Grow at 8.8% CAGR

The Transforming Growth Factors market in the U.S. is estimated at US$110.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$113.1 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Transforming Growth Factors Market - Key Trends & Drivers Summarized

Why Are Transforming Growth Factors at the Forefront of Regenerative Medicine?

Transforming Growth Factors (TGFs), particularly TGF-β and TGF-α, are pivotal signaling proteins that regulate cell growth, differentiation, and immune response. Their critical role in tissue repair, fibrosis, angiogenesis, and inflammation makes them central to therapeutic research across regenerative medicine, oncology, and immunology. TGFs are instrumental in modulating the extracellular matrix and activating pathways involved in wound healing, organ regeneration, and immune tolerance.

In drug development, TGFs are targeted for both agonist and antagonist applications. While overexpression is linked to fibrosis and tumor progression, controlled modulation has shown therapeutic potential in diseases such as multiple sclerosis, chronic ulcers, and cardiac remodeling. Their multifunctional nature is unlocking novel approaches in tissue engineering, including scaffold functionalization and bioactive implant coatings, which leverage TGF signaling to promote tissue integration and vascularization.

How Are Therapeutic Applications and Delivery Methods Evolving?

Biotech research is increasingly focused on fine-tuning TGF signaling to avoid off-target effects and disease-promoting cascades. Monoclonal antibodies, ligand traps, and small molecule inhibitors are being developed to selectively block TGF-β activity in conditions such as pulmonary fibrosis and pancreatic cancer. Conversely, recombinant growth factors and TGF-loaded nanoparticles are being employed to enhance tissue repair in orthopedic and dermatological applications.

Advancements in localized drug delivery-such as hydrogel matrices, implantable biomaterials, and gene therapy vectors-are helping overcome challenges related to systemic toxicity and dose control. These delivery strategies enable site-specific activation or inhibition of TGFs, improving therapeutic outcomes. The integration of TGFs into advanced cell therapies, such as stem cell implants and CAR-T cell regulation, is also emerging as a frontier in personalized and precision medicine.

The Growth in the Transforming Growth Factors Market is Driven by Several Factors…

Growth is driven by expanding applications in regenerative medicine, oncology, and immunotherapy, alongside increasing use in biomaterial-based drug delivery systems. Advances in recombinant protein engineering and gene modulation tools are enabling targeted TGF manipulation. Rising investments in chronic wound care, tissue engineering, and fibrosis-related disease research are accelerating clinical pipeline development. Additionally, demand for functional biomolecules in organoids and 3D cell culture platforms is further enhancing commercial and therapeutic interest in TGF signaling proteins.

SCOPE OF STUDY:

The report analyzes the Transforming Growth Factors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Activin, Bone Transforming Morphogenetic Proteins, TGF-Beta Proteins); Grade (GMP-Grade, Non-GMP- Grade); Application (Oncology Research Application, Hematology Research Application, Wound Healing Research Application, Dermatology Research Application, Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use, CMO & CDMO End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Abcam plc
  • Abnova Corporation
  • Abzena, Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology
  • Creative Biomart
  • GenScript Biotech Corporation
  • GenScript ProBio
  • Merck KGaA
  • Novoprotein Scientific
  • PeproTech, Inc.
  • Peptide Institute, Inc.
  • ProSpec-Tany TechnoGene Ltd
  • Proteintech Group Inc.
  • R&D Systems (Bio-Techne)
  • RayBiotech, Inc.
  • Sigma-Aldrich (Merck)
  • Sino Biological Inc.
  • Stemcell Technologies Inc.
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transforming Growth Factors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Targeted Biologics Fuels Research in Transforming Growth Factor Pathways
    • Increased Use of TGF Inhibitors in Oncology Supports Expansion in Anti-Cancer Therapeutics
    • Growth in Fibrosis Research Drives Interest in TGF-? Pathway Modulation
    • Emergence of Gene Therapy and Antibody Drug Conjugates Enhances Therapeutic Use of TGFs
    • Expansion in Wound Healing and Regenerative Medicine Applications Strengthens Pipeline Potential
    • Demand for Biomarkers in Autoimmune Disease Management Fuels Diagnostic Applications of TGF
    • Increased Licensing of TGF-Modulating Molecules Supports Early-Stage Clinical Development
    • Growth in Chronic Inflammation and Tissue Remodeling Research Drives Demand in Biopharma R&D
    • Integration With Stem Cell Therapy Platforms Supports Tissue Engineering Innovations
    • Use in Personalized Medicine Strategies Enhances Targeted TGF Pathway Blockade
    • Academic and CRO-Based Clinical Trials Boost Validation of New Indications
    • Interest in Multi-Pathway Modulators Drives Combination Therapy Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transforming Growth Factors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transforming Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Transforming Growth Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Transforming Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Activin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Activin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Activin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bone Transforming Morphogenetic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bone Transforming Morphogenetic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Bone Transforming Morphogenetic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for TGF-Beta Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for TGF-Beta Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for TGF-Beta Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cardiovascular Disease & Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cardiovascular Disease & Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cardiovascular Disease & Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cell Therapy & Ex Vivo Manufacturing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cell Therapy & Ex Vivo Manufacturing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cell Therapy & Ex Vivo Manufacturing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Oncology Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Oncology Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hematology Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hematology Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hematology Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Wound Healing Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Wound Healing Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Wound Healing Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Dermatology Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Dermatology Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Dermatology Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Research Centers & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Research Centers & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Research Centers & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for CMO & CDMO End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for CMO & CDMO End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for CMO & CDMO End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for GMP-Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for GMP-Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for GMP-Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Non-GMP- Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Non-GMP- Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Non-GMP- Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • JAPAN
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • CHINA
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 86: China Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: China 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: China 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • EUROPE
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Transforming Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Transforming Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • FRANCE
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 113: France Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: France 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: France 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: France 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • GERMANY
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 149: UK Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: UK 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: UK 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Transforming Growth Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • INDIA
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 224: India Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: India 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: India 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: India 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Transforming Growth Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Transforming Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Brazil 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Brazil 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Mexico 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Mexico 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Transforming Growth Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Transforming Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 337: Middle East 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 346: Iran 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 349: Iran 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 358: Israel 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 361: Israel 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 382: UAE 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 385: UAE 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030
  • AFRICA
    • Transforming Growth Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Transforming Growth Factors by Product - Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Transforming Growth Factors by Product - Percentage Breakdown of Value Sales for Activin, Bone Transforming Morphogenetic Proteins and TGF-Beta Proteins for the Years 2014, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Transforming Growth Factors by Application - Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for Transforming Growth Factors by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease & Diabetes Application, Cell Therapy & Ex Vivo Manufacturing Application, Other Applications, Oncology Research Application, Hematology Research Application, Wound Healing Research Application and Dermatology Research Application for the Years 2014, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Transforming Growth Factors by End-Use - Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 406: Africa 16-Year Perspective for Transforming Growth Factors by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Centers & Academic Institutes End-Use and CMO & CDMO End-Use for the Years 2014, 2025 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Transforming Growth Factors by Grade - GMP-Grade and Non-GMP- Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 409: Africa 16-Year Perspective for Transforming Growth Factors by Grade - Percentage Breakdown of Value Sales for GMP-Grade and Non-GMP- Grade for the Years 2014, 2025 & 2030

IV. COMPETITION

トランスフォーミング成長因子の世界市場
発行日
発行
Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報
英文 481 Pages
納期
即日から翌営業日

関連レポート

トランスフォーミング増殖因子（TGF）市場：市場の洞察、競合情勢、および市場予測（2033年）
発行日
2026年05月28日

サンプル依頼リストに
追加しました

リストを確認する
トランスフォーミング増殖因子市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
発行日
2024年06月06日

サンプル依頼リストに
追加しました

リストを確認する